Market Overview

UPDATE: Barrington Raises PT on NuVaisve on Multiple Positive Factors

Related NUVA
NuVasive Gets Unfavorable Trademark Verdict - Analyst Blog
NuVasive Announces $30M Unfavorable Jury Verdict for Use of Trade-Name 'NeuroVision' 8-K

In a report published Tuesday, Barrington Research analyst Charley Jones reiterated an Outperform rating on NuVasive (NASDAQ: NUVA), and raised the price target from $25.00 to $27.00.

In the report, Jones noted, “We are reiterating our OUTPERFORM investment rating of NUVA and increasing our price target to $27 from $25 based on the company's technology leadership, increasing revenue per procedure, growing sales bag and strong history of market share gains.Our price target is based on an EV/Revenue multiple of 1.3x our FY/13 revenue estimate of $655 million.”

NuVasive closed on Monday at $23.26.

Posted-In: Barrington ResearchAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (NUVA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free